secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2021-08-11T23:59:59+00:00
Accession:  0001564590-21-043472
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Arcus board member Quigley resigns; Linda Higgins appointed as Gilead designee
------------------------------------------------------------------------------

- Michael Quigley resigned from Arcus board effective upon appointment of Gilead's new designee, following his departure from Gilead.
- Linda Higgins, SVP of Research at Gilead, appointed as Class III director; she previously led Biology at Gilead since 2010.
- Higgins will not receive compensation for Arcus board service; standard indemnification agreement expected.
- Changes effective August 10, 2021, under the Investor Rights Agreement with Gilead dated May 2020.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000156459021043472/0001564590-21-043472-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000156459021043472/rcus-8k_20210810.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-043472

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer